Introduction
Type 2 diabetes is characterized by insulin resistance and pancreatic β cell dysfunction. Hyperglycemia occurs by a progressive failure of pancreatic β cells to secrete sufficient amounts of insulin to compensate for the insulin resistance. Thus, dysfunction of β cell secretion is a key element in the pathophysiology of type 2 diabetes. Increased demand for insulin secretion under certain conditions, such as obesity and long-term treatment with sulfonylureas, may result in β cell overload and insulin secretion deficiency. β cell dysfunction under these conditions is often termed "pancreatic β cell exhaustion." Several studies have shown that β cell mass (both number and individual volume of cells) is reduced in patients with type 2 diabetes (1, 2), an event possibly due to apoptotic death of β cells and to a reduction of cell proliferation. Precise mechanisms remain to be determined.
One of the characteristic features of β cells is a highly developed endoplasmic reticulum (ER), apparently due to heavy engagement in insulin secretion. The ER serves several important functions, including posttranslational modification, folding, and assembly of newly synthesized secretory proteins, and its proper function is essential to cell survival. The ER is regulated by signaling pathways that respond to an accumulation of unfolded or misfolded proteins in the organelle. At least four functionally distinct responses have been identified (3) (4) (5) . The first response involves upregulation of genes encoding ER chaperone proteins, such as Bip/GRP78 and GRP94, to increase protein folding activity and prevent protein aggregation. The second response consists of translational attenuation, to reduce the load of new protein synthesis and prevent further accumulation of unfolded proteins. The third is degradation of misfolded proteins in the ER, a process known as ER-associated degradation. The misfolded proteins are transported from the ER to the cytosol, where ubiquitin-conjugating enzymes target them for degradation by the 26S proteasome. The last response is apoptosis, which occurs when functions of the ER are extensively impaired. This apoptotic event is mediated by transcriptional activation of the gene for Chop (C/EBP homologus protein, also known as GADD153), a member of the C/EBP family of transcription factors (6, 7) , and by activation of ER-associated caspase-12 (8) . The upstream components of these response pathways consist of several transmembrane proteins in the ER that transmit stress signals in response to perturbation of protein folding. ER stress transducer proteins, including Ire1α and PERK, are expressed at high levels in β cells. Mice lacking PERK were found to exhibit β cell Overload of pancreatic β cells in conditions such as hyperglycemia, obesity, and long-term treatment with sulfonylureas leads to β cell exhaustion and type 2 diabetes. Because β cell mass declines under these conditions, apparently as a result of apoptosis, we speculated that overload kills β cells as a result of endoplasmic reticulum (ER) stress. The Akita mouse, which carries a conformation-altering missense mutation (Cys96Tyr) in Insulin 2, likewise exhibits hyperglycemia and a reduced β cell mass. In the development of diabetes in Akita mice, mRNAs for the ER chaperone Bip and the ER stress-associated apoptosis factor Chop were induced in the pancreas. Overexpression of the mutant insulin in mouse MIN6 β cells induced Chop expression and led to apoptosis. Targeted disruption of the Chop gene delayed the onset of diabetes in heterozygous Akita mice by 8-10 weeks. We conclude that ER overload in β cells causes ER stress and leads to apoptosis via Chop induction. Our findings suggest a new therapeutic approach for preventing the onset of diabetes by inhibiting Chop induction or by increasing chaperone capacity in the ER. death and to develop diabetes (9) . Mice with a homozygous mutation at the eIF2α phosphorylation site have a β cell deficiency (10) . These data suggest that β cells are affected by ER stress under conditions lacking any sign of insulin resistance (such as obesity). Moreover, we found that nitric oxide-induced apoptosis in β cells is mediated by the ER-stress pathway (11) . Nitric oxide depletes ER Ca 2+ , causes ER stress, and leads to apoptosis through Chop induction. Pancreatic islets from Chop knockout mice showed resistance to nitric oxide. High expression of these ER stress transducer proteins may be necessary for strict quality control of secretory proteins in β cells, and the disturbance in protein traffic in the ER may lead to cell death.
A mutant mouse line, called the Akita mouse, which spontaneously develops hyperglycemia with reduced β cell mass, but without insulitis or obesity, was established (12, 13) . Genetic analysis revealed that a mutation of the insulin 2 gene (Ins2) (Cys96Tyr) is responsible for the diabetic phenotype in this mouse (14) . This mutation disrupts a disulfide bond in insulin between the A and B chains and is thought to induce a drastic conformational change of this molecule. We speculated that this mouse could serve as a diabetic model related to ER stress. We now report that progressive hyperglycemia in the Akita mouse is accompanied by Chop induction and β cell apoptosis. Targeted disruption in the Chop gene delayed the onset of disease in heterozygous Akita mice. These results highlight the importance of chronic ER stress in β cell apoptosis and in the reduced islet mass observed in type 2 diabetes.
Methods
Generation of animal models. All procedures involving these animals were approved by the Animal Care and Use Committee of Kumamoto University. Mice lacking the Chop gene (C57BL/6 background) were generated as described (11) . Akita mice, which carry the Cys96Tyr (C96Y) missense mutation in the Ins2 gene, were established on a C57BL/6 background and characterized as described (12, 13 Genotyping of the double-mutant mice. The genotype for Ins2 was determined by RFLP, as described (14) . The genotype for Chop was determined by PCR. The following primers were used: the sense primer was 5′-GAGAAAAAAAGAGTACAAATGGCCTGG-3′, and the antisense primers were 5′-AATTTCATCTGAGGACAGG-ACCTCCTG-3′ (derived from the neomycin resistance gene), and 5′-ATCGCCTTCTATCGCCTTCTTGACGAG-3′ (derived from the Chop gene). The thermal cycle reaction was performed as follows: 94°C for 2 minutes, followed by 35 cycles at 94°C for 15 seconds, 55°C for 30 seconds, 68°C for 2 minutes, and 72°C for 7 minutes. The wild-type and recombinant alleles each yielded a transcript of 1.3 kb.
Northern blot analysis. Total RNA (2.0 µg per lane) was electrophoresed in formaldehyde-agarose gels, and blotted onto nylon membranes. Northern blot analysis was done as described (15) . Digoxigenin-labeled antisense RNA probes for mouse insulin 2 (nucleotides 2344-3026; GenBank accession number NM_008387), mouse Chop (11), and mouse Bip (nucleotides 1629-1859; GenBank accession number AJ002387) were synthesized using a DIG RNA labeling kit (Roche Molecular Biochemicals, Indianapolis, Indiana, USA). Chemiluminescence signals were quantified using a chemiluminescence image analyzer (LAS-1000plus; Fuji Photo Film Co., Tokyo, Japan).
Concentrations of blood glucose and plasma insulin. Blood glucose concentration was measured by the mutarotase/glucose dehydrogenase method, using a glucose analyzer (HemoCue AB, Ängelholm, Sweden). Plasma insulin concentration was measured by a sandwichtype enzyme immunoassay using an insulin ELISA kit (Shibayagi Co., Shibukawa, Japan).
Insulin content in the pancreas. Pancreata were removed from mice and immediately frozen in liquid nitrogen. Protein extracts were prepared using the acid/ethanol method (16) . Briefly, the tissue was homogenized in acid/ethanol (0.18 M HCl in 70% ethanol), and the homogenate was sonicated for 15 seconds and kept at 4°C for 24 hours. Homogenates were then centrifuged at 500 g for 10 minutes at 4°C, and the supernatant was stored at -20°C. After neutralization, insulin in the extracts was measured using insulin ELISA as described above. Protein in tissue extracts was determined by the Bradford method.
Immunostaining and TUNEL assay. Pancreas specimens were fixed with buffered 4% paraformaldehyde solution, and embedded in paraffin. Blocks were cut into 5-µm-thick sections. Sections were stained with a rabbit anti-insulin polyclonal antibody (Santa Cruz Biotechnology Inc., Santa Cruz, California, USA) or a mouse antiChop monoclonal antibody (Santa Cruz Biotechnology Inc.) as the primary antibody; Cy3-labeled anti-rabbit IgG (Amersham Pharmacia Biotech, Piscataway, New Jersey, USA) or Alexa Fluor 488-labeled anti-mouse IgG (Molecular Probes Inc., Eugene, Oregon, USA) was used as the secondary antibody. For apoptosis detection, the TUNEL assay was performed using an in situ apoptosis detection kit (Takara Shuzo Co., Otsu, Japan). The tissues were viewed under an Olympus fluorescence microscope equipped with a krypton-argon laser, and images were acquired using a C5810 color chilled 3CCD video camera system (Hamamatsu Photonics KK, Hamamatsu, Japan).
Cell culture, transfection, and apoptosis analysis. Mouse insulinoma MIN6 cells were cultured in 60-mm collagen-coated dishes in DMEM supplemented with 25 mM glucose and 10% FCS, as described (11).
Plasmid DNAs (5 µg in total) were transfected into MIN6 cells using LipofectAMINE 2000 (Invitrogen Corp., Carlsbad, California, USA). An expression vector for enhanced green fluorescent protein (pEGFP) and an ER localization vector that expresses enhanced yellow fluorescent protein (pEYFP-ER) were purchased from Clontech Laboratories Inc. (Emeryville, California, USA). The mouse insulin 2 cDNA clone was isolated by RT-PCR, using mRNA from MIN6 cells. To introduce the Cys96Tyr substitution, overlap extension PCR mutagenesis was done using the mutant primers 5′-AGCGTGGCATTGTAGATCAGTGCTACACCA-3′ and 5′-TGGTGTAGCACTGATCTACAATGCCACGCT-3′. The mutation was confirmed by DNA sequencing. Construction of pcDNA-Ins2 WT and pcDNA-Ins2 C96Y was performed by inserting the full-length cDNA fragment for mouse wild-type or Cys96Tyr, mutant insulin 2 respectively, into the mammalian expression vector pcDNA3.1(-) (Invitrogen Corp.) after linker attachment. To generate the pIns2 WT -EGFP and the pIns2 C96Y -EGFP constructs, in which EGFP was located at the C-terminus of insulin, the full-length cDNA fragment, full-length except for its termination codon, was inserted into the mammalian expression vector pEGFP-N1 (Clontech Laboratories Inc.).
For the apoptosis assay, 48 hours after transfection, the medium was carefully removed to collect detached cells. Adherent cells were recovered by trypsinization and mixed with the separated medium. Cells were pelleted and resuspended. To analyze apoptotic changes of nuclei, cells were fixed in 4% formaldehyde in PBS for 30 minutes, stained with Hoechst 33258, and observed under a fluorescence microscope. To detect DNA ladder formation, DNA was extracted from cells, electrophoresed in 2% agarose gel, stained with SYBR Green I (Molecular Probes Inc.), and visualized by UV transillumination. Annexin V staining was performed using the Annexin V-Cy3 apoptosis detection kit (Medical and Biological Laboratories Co., Nagoya, Japan) according to the manufacturer's instructions.
Statistical analysis. Data were expressed as mean ± SD. Statistical significance of differences between groups was evaluated using the unpaired Student t test. When the P value was less than 0.05, the difference was considered to be statistically significant.
Results
Diabetic phenotype of mice with Ins2 mutation. To examine the phenotypic consequences of Ins2 mutation in the Akita mouse, we monitored blood glucose levels in each genotype (Figure 1 ). Ins2 C96Y/C96Y mice developed hyperglycemia at 2 weeks of age, and blood glucose levels continued to increase up to 700 mg/dl at 10 weeks of age. At 2 weeks of age, Ins2 WT/C96Y mice had euglycemia. They developed diabetes between 4 and 8 weeks of age. Thus, the severity and the onset of disease correlated well with number of the mutant allele. All Akita mice developed diabetes (100% penetration) and showed the simultaneous onset of disease in each genotype. There was no gender difference in onset of the disease. However, the increase in blood glucose levels was more marked in male than in female mice, both Ins2 C96Y/C96Y and Ins2 WT/C96Y .
Induction of ER stress-associated genes in the pancreas of Akita mice. The Ins2 mutation in Akita mice disrupts a disulfide bond between the A and B chains of insulin, and can induce a drastic conformational change in the molecule. We speculated that this misfolded insulin could cause ER stress. To check ER stress in the Akita mice, Northern blot analysis for insulin and ER stress-associated proteins in pancreas was done ( Figure  2) . In Ins2 WT/WT mice, insulin mRNA gradually increased with age (data not shown). At 3 weeks of age, insulin mRNA was higher in Ins2 WT/C96Y mice than in Ins2 WT/WT mice, and was higher yet in Ins2 C96Y/C96Y mice. At 6 weeks of age, insulin mRNA was higher in Ins2 WT/C96Y mice than in controls, but was similar between Ins2 WT/C96Y mice and Ins2 C96Y/C96Y mice. In contrast, at 9 weeks of age, the mRNA was slightly higher in Ins2 WT/C96Y mice than in controls, and was much lower in Ins2 C96Y/C96Y mice than in controls. This decrease in insulin mRNA in Ins2 C96Y/C96Y mice appears to be due to a loss of β cells (see below). Of note is that the onset of diabetes is associated with an increase in insulin mRNA. This suggests that insulin mRNA is induced to compensate for the deficiency in secretion of active insulin. Chop/GADD153, a transcription factor that plays a role in growth arrest and cell death, and Bip/GRP78, an ER chaperone, are induced by ER stress. Chop mRNA was much higher in Ins2 C96Y/C96Y mice than in controls at 3 weeks of age. It was also much higher than that in controls in both Ins2 WT/C96Y mice and Ins2 C96Y/C96Y mice at 6 weeks of age, and in Ins2 WT/C96Y mice at 9 weeks of age. The profile of fluctuation in Chop mRNA was similar to that of insulin mRNA. Bip mRNA and Chop mRNA changed in a similar manner. These results indicate that β cells in both heterozygous and homozygous mutant mice are subjected to ER stress, and that the ER stress is closely associated with the induction of insulin mRNA.
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Overexpression of insulin 2 C96Y leads to apoptosis in MIN6 cells. Induction of Chop and postnatal hyperglycemia
in Ins2 C96Y mice suggests that the mutant insulin causes ER stress and leads to apoptosis in β cells via Chop induction. To test this hypothesis, we overexpressed wild-type and Cys96Tyr mutant insulin 2 in MIN6 cells (Figure 3) . We generated fusions of mouse insulin and EGFP for real-time monitoring of apoptosis (Figure 3a) . When cells were transfected with the pIns2 WT -EGFP plasmid, fluorescence was observed in transfected cells 24 hours after transfection, and apparently increased with time up to 60 hours (Figure 3a) . When cells were transfected with the pIns2 C96Y -EGFP plasmid, fluorescent cells were morphologically similar to those expressing Ins2 WT -EGFP at 24 hours. However, cells expressing Ins2 C96Y -EGFP became round and detached from dishes at 36 hours and thereafter. These results indicate that cells expressing Ins2 C96Y -EGFP undergo cell death.
To exclude artificial effects of fusion proteins, cells were cotransfected with an EYFP-ER expression plasmid and either the pcDNA-Ins2 WT plasmid or the pcDNA-Ins2 C96Y plasmid. Cells expressing Ins2 WT showed ER-like fluorescence, whereas cells expressing Ins2 C96Y became round and detached from dishes (Figure 3b) . Staining with Hoechst 33258 revealed that cells expressing Ins2 C96Y undergo apoptosis (Figure 3c ). Transfection with pcDNA-Ins2 C96Y plasmid led to formation of DNA ladders, which is characteristic of apoptotic cells (Figure 3d ). Annexin V staining revealed that cells expressing Ins2 C96Y undergo apoptosis ( Figure  3e ). Considering these results together, we conclude that overexpression of Ins2 C96Y causes ER stress and leads to Chop-mediated apoptosis. There was no statistically significant difference in body weight among Chop +/+ , Chop +/-, and Chop -/-male mice. The female Chop -/-mice were seen to have higher body weight than female Chop +/+ animals had. In addition, the development of obesity and fat deposits in the Chop -/-mice after 16 weeks of age appeared to be accelerated (data not shown). It has been suggested that Chop inhibits adipose differentiation by interfering with the accumulation of adipogenic C/EBP isoforms (17, 18) . Therefore, we speculate that targeted disruption of the Chop gene results in obesity by increasing adipocyte differentiation. In this study, the Chop -/-mice, generated on a C57BL/6 strain, were backcrossed only two generations from the original 129/Sv × C57BL/6 mice. Therefore, it is also possible that the 129/Sv background influences body weight. Figure 6 ). Both Ins2 WT/C96Y Chop +/+ and Ins2 WT/C96Y Chop +/-mice developed hyperglycemia beginning at 4 weeks of age. Blood glucose levels in these mice increased up to about 800 mg/dl, at which point mice were 20 weeks of age. In contrast, blood glucose in Ins2 WT/C96Y Chop -/-mice remained unchanged (less than 250 mg/dl) until the mice reached 8 weeks of age. At that point levels began to increase; at 20 weeks the blood glucose level in these mice was about 500 mg/dl. Thus, disruption of the Chop gene delayed the onset of diabetes in Ins2 WT/C96Y mice by 8-10 weeks; hyperglycemia was somewhat overcome but was not prevented.
Characteristics of double-mutant mice with Ins2 mutation and Chop disruption. To further investigate the involvement of Chop in ER stress

Disruption of the Chop gene protects islet cells of
Discussion
We obtained evidence that mutation in Akita mice causes ER stress, induces Chop mRNA, and leads to the apoptosis of β cells. Targeted disruption of the Chop gene significantly prevented Ins2 C96Y -induced diabetes by decreasing ER stress-mediated apoptosis in β cells. Therefore, perturbation in functions of the ER in β cells leads to diabetes through Chop induction.
The ER has a mechanism to monitor protein folding called "quality control" (19) . In Ins2 C96Y mutant mice, the mutant insulin is not secreted; it is trapped in the ER and is intracellularly degraded (14) . This mouse has two nonallelic insulin genes (Ins1 and Ins2). In wild-type mice, Ins2 transcripts represent the majority of total insulin. Although Ins2 C96Y mice develop severe diabetes, single-mutant mice that are either Ins1 -/-or Ins2 -/-do not, and plasma insulin levels in these mice are normal (20) . Hence, we speculated that diabetes in Ins2 C96Y mice is induced by β cell disruption mediated by ER stress, rather than by the loss of active insulin. This notion is supported by evidence of apoptosis and the induction of Chop mRNA in the pancreas of Ins2 C96Y mutant mice. In Ins2 -/-mutant mice, to overcome insulin deficiency, the β cell mass is increased and synthesis of insulin 1 is enhanced (20) . In Ins 2C96Y mice, on the other hand, expression of the insulin gene is upregulated to compensate for insulin deficiency, but synthesized mutant insulin induces ER stress, β cell death follows, and glucose metabolism is decreased (Figure 2) . β cells are strongly engaged in protein secretion and have highly developed ER. ER stress transducer proteins, including Ire1α and PERK, are expressed at high levels in β cells. This high expression may be necessary for strict quality control of secretory proteins in β cells, and disturbance of protein traffic in ER may lead to cell death. Two recent studies using genetically engineered mice revealed that PERK disruption and defective eIF2α phosphorylation results in β cell insufficiency, thereby demonstrating that the PERK-eIF2α pathway plays an important role in translational control in ER stress (9, 10) . Postnatally increased apoptosis in β cells was observed in PERK -/-mice. Electron micrographs of islets in PERK -/-mice revealed dilated ER in β cells, and a reduced number and size of secretory granules. Similar changes are observed in islets of Akita mice (14) . Mutations in the human PERK gene cause Wolcott-Rallison syndrome, an autosomal recessive disease with severe diabetes that develops in infancy (21) . Patients have pancreatic hypoplasia and a reduced number of β cells (22) . Taken together, these results suggest that chronic ER stress results in hyperglycemia due to reduction in β cell mass, and that β cells are most susceptible to ER stress.
In contrast to patients with type 1 diabetes, those with type 2 diabetes are often hyperinsulinemic during the prediabetic or early diabetic phase. Overload of pancreatic β cells under conditions such as hyperglycemia, obesity, and long-term treatment with sulfonylureas is often observed in type 2 diabetes. This increased demand of insulin may exhaust the secretory capacity of β cells. Indeed, when MIN6 cells were transfected with wild-type insulin, highly overexpressed cells were prone to apoptosis (data not shown). These findings support the idea that chronic ER stress caused by excessive demand of insulin is responsible for β cell exhaustion. However, disruption of the Chop gene failed to prevent diabetes in Ins2 WT/C96Y mice, although it did delay the onset of disease. In the case of Ins2 C96Y/C96Y mice, disruption of the Chop gene could not delay the onset of diabetes. Chop induction in response to ER stress is highly dependent on PERK (23) . In islets of PERK -/-mice, induction of Chop is attenuated, but β cells undergo apoptosis (9) . Thus, the involvement of other death pathways, such as activation of JNK via Ire1α (24) and activation of caspase-12 (8), seems likely.
There are similarities in development between type 1 and type 2 diabetes. Once mild hyperglycemia occurs, a common pathway of diabetes leads to further severe hyperglycemia. Our results provide evidence suggesting that the ER in β cells modifies the development of diabetes. We propose that overload of β cells causes chronic ER stress and leads to apoptosis of β cells via Chop induction. Therefore, targeted suppression of Chop expression or its function in β cells may be a new therapeutic approach for preventing the onset of both type 1 and type 2 diabetes.
